Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Jenna who wrote (81719)	2/4/2000 8:03:00 AM
From: macduff3	Read Replies (2) \| Respond to of 120523

Earnings calender access; Is anyone else unable to access earnings calender for next week?

To: Jenna who wrote (81719)	2/4/2000 8:55:00 AM
From: ronco	Respond to of 120523

Jenna, EVIS has strong fundamentals with a beautiful chart. Do you have any thoughts regarding this International Internet play; it appears poised for a major move. Thank you in advance for your input. Dave

To: Jenna who wrote (81719)	2/4/2000 10:08:00 AM
From: Probart	Respond to of 120523

Jenna, PFSW one to add to future lists. Long @ 33 and 45. "Our adjusted service fee revenues of $14.0 million exceeded our target this quarter, and reflects growth of 351% over the prior year (as adjusted)," said Mark C. Layton, President and CEO of PFSweb. "The significant increase was a result of new client activity, the addition of Daisytek as a client, and strong growth in Internet based holiday sales volume. We were fortunate to have added approximately 15 new clients during calendar year 1999, of which the majority became operational in the last four months of the year. Our adjusted gross profit percentage for the three months ended Dec. 31, 1999, was 33.1%, which represents a slight decline versus previous sequential quarters. This decline was expected as a result of changes in customer mix as well as incremental investments in personnel, technology, capacity and infrastructure during the latter half of 1999."

To: Jenna who wrote (81719)	2/4/2000 12:17:00 PM
From: rod runyan	Read Replies (1) \| Respond to of 120523

Watchlist for 2-1 #12 is up 12 3/16 to 37 1/4 on good news. Thank you Jenna. rod <<INTEGRILIN Stent Study Halted Early Due to Positive Results The results of the interim analysis were reviewed by an independent Data Safety Monitoring Committee (DSMC) which determined that the study should be stopped due to the highly significant reduction in the combined incidence of death or myocardial infarction with INTEGRILIN compared with placebo over 30 days (P=0.0011) following a stenting procedure. A significant reduction was seen as early as 48 hours (P=0.0017) in the interim analysis of 1,758 patients. ''Given the dramatic reduction in clinically serious outcomes achieved, the committee unanimously agreed that the placebo patients should not be denied access to this type of therapy,'' stated Robert M. Califf, MD, Associate Vice Chancellor for Clinical Research at Duke University Medical Center We now have convincing evidence that INTEGRILIN represents a highly efficacious therapy for these vulnerable patients.'' ''We can now achieve a robust reduction in death or MI associated with intracoronary stenting, coupled with the reversibility and affordability of INTEGRILIN,'' stated James E. Tcheng, MD, Assistant Professor of Medicine at Duke University Medical Center and lead investigator for ESPRIT. Review of the specific data from the study will be made public at an upcoming scientific forum. ">>